Please use this identifier to cite or link to this item:
|Title:||Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.|
Coronary Artery Disease
|Citation:||Eur. Heart J..2016 Sep;(37)35:2701-9|
|Abstract:||Metal absorbable scaffolds constitute a conceptually attractive alternative to polymeric scaffolds. Promising 6-month outcomes of a second-generation drug-eluting absorbable metal scaffold (DREAMS 2G), consisting of an absorbable magnesium scaffold backbone, have been reported. We assessed the 12-month safety and performance of this novel device.|
|Appears in Collections:||Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.